Related Experiment Videos
[Therapeutic immunoadsorption in Goodpasture disease]
F Moreso1, R Poveda, S Gil-Vernet
1Servicio de Nefrología, Ciudad Sanitaria y Universitaria de Vellvitge, L'Hospitalet de Llobregat, Barcelona.
Medicina Clinica
|June 10, 1995
Summary
Immunoabsorption (IA) effectively removes antiglomerular basement membrane (GBM) antibodies, improving outcomes for Goodpasture disease patients. Early IA treatment can prevent kidney failure and respiratory complications.
Area of Science:
- Nephrology
- Immunology
- Pulmonology
Background:
- Goodpasture's disease is characterized by circulating antiglomerular basement membrane (GBM) antibodies.
- Plasmapheresis (PP) improves prognosis, but immunoabsorption (IA) may offer more effective immunoglobulin extraction.
Observation:
- Two patients with Goodpasture disease received IA therapy.
- One patient showed no response to three PP sessions before commencing IA.
Findings:
- IA rapidly decreased anti-GBM antibody levels and improved respiratory failure in both patients.
- IA was effective in treating pulmonary hemorrhage and preventing kidney disease progression when initiated early.
- In advanced disease, IA did not alter dialysis requirements.
Implications:
- Immunoabsorption is a promising therapeutic option for managing pulmonary hemorrhage in Goodpasture's disease.
- Early intervention with IA may preserve renal function and prevent end-stage renal disease.